Lasolvan Max, capsules 75 mg 10 pcs

Indications

Active ingredient

Composition

Active ingredients:

ambroxol hydrochloride 75 mg;

Supplements:

crospovidone 12.55 mg,

carnauba wax 18.31 mg,

stearyl alcohol 110.94 mg,

Magnesium stearate 1.20 mg;

Capsule shell composition:

gelatin 52.307 mg, purified water 9.135 mg, titanium dioxide (E171) 1.008 mg, iron oxide red dye (E172) 0.150 mg, iron oxide yellow dye (E172) 0.398 mg;

The composition of the ink:

shellac, titanium dioxide.

How to take, the dosage

Adults:1 capsule once daily.

The capsule should be swallowed whole with plenty of liquid.

You may not open or chew the capsule!

The pellets inside the capsule release the active ingredient as they pass through the digestive system.

General Information.

It can be taken with a meal or on an empty stomach.

The course is 14 days for the treatment of acute respiratory conditions and for the initial treatment of chronic conditions.

If the condition does not improve with the current therapy of acute respiratory conditions, medical attention should be sought.

Interaction

No clinically significant adverse interactions with other drugs have been reported.

The combined use with anti-cough drugs leads to difficulty of sputum discharge on the background of cough suppression.

It increases penetration and concentration in the bronchial secretion of amoxicillin, cefuroxime and erythromycin.

Special Instructions

Very rare cases of severe skin lesions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported with ambroxol hydrochloride. They are mainly due to the severity of the underlying disease and concomitant treatment.

In addition, in the early stages of Stevens-Johnson syndrome and toxic epidermal necrolysis, patients may show signs of the onset of nonspecific disease with the following symptoms: increased body temperature, full body pain, rhinitis, cough and sore throat.

The appearance of these signs can lead to unnecessary symptomatic treatment with cold medications. If skin lesions appear, the patient is immediately examined by a physician and ambroxol hydrochloride is discontinued.

Patients with decompensated renal insufficiency should use the drug only after consulting a physician.

Fertility, pregnancy and lactation

Ambroxol hydrochloride penetrates the placental barrier. Preclinical studies have shown no direct or indirect adverse effects on pregnancy, fetal development, labor and postnatal development.

The drug is not recommended for use during the first trimester of pregnancy. Use with caution in the II-III trimesters of pregnancy and lactation.

Ambroxol hydrochloride penetrates into breast milk, however, when prescribed in therapeutic doses, does not have adverse effects on the baby.

Preclinical studies have shown no direct or indirect adverse effects on fertility.

Specific effects of the drug on driving or potentially dangerous machinery

There are no reported cases of the drug affecting driving or operating ability in the post-marketing period. No studies have been conducted.

Contraindications

Side effects

Gastrointestinal disorders

Frequent (≥ 1/100 – < 1/10):

Infrequent(≥ 1/1,000 – < 1/100):

Rare (≥ 1/10,000 – < 1/1,000):

Immune system disorders

Not known:

Skin and subcutaneous tissue disorders

Rare(≥ 1/10,000 to < 1/1,000):

Not known:

Overdose

Symptoms: nausea, vomiting, diarrhea, dyspepsia.

Treatment: symptomatic therapy.

Similarities